Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 239

Similar articles for PubMed (Select 19463509)

1.

Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.

Allen LaPointe NM, Zhou Y, Stafford JA, Hernandez AF, Kramer JM, Anstrom KJ.

Am J Cardiol. 2009 Jun 1;103(11):1518-24. doi: 10.1016/j.amjcard.2009.01.363. Epub 2009 Apr 8.

PMID:
19463509
3.

Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.

Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.

J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. doi: 10.1016/j.jacc.2010.01.024.

4.
5.
6.

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.

Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM.

Circulation. 2006 Jan 17;113(2):203-12. Epub 2006 Jan 9.

7.

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.

Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML; APPROACH Investigators.

J Am Coll Cardiol. 2004 Oct 19;44(8):1587-92.

8.
9.

Angiotensin receptor blockers for heart failure.

Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD003040. doi: 10.1002/14651858.CD003040.pub2. Review.

PMID:
22513909
10.

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.

McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Piña IL, Soler-Soler J, Swedberg K.

Eur J Heart Fail. 2005 Aug;7(5):710-21.

PMID:
16087129
11.

[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction].

Ruta J, Ptaszyński P, Maciejewski M, Goch JH, Chizyński K.

Wiad Lek. 2006;59(9-10):649-53. Polish.

PMID:
17338123
13.

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.

Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moyé L, Pfeffer M.

J Am Coll Cardiol. 1997 Feb;29(2):229-36.

PMID:
9014971
14.

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group.

Circulation. 2007 Jul 3;116(1):49-56. Epub 2007 Jun 18.

15.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
16.

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.

Marazzi G, Iellamo F, Volterrani M, Caminiti G, Madonna M, Arisi G, Massaro R, Righi D, Rosano GM.

Am J Cardiol. 2011 Jan 15;107(2):215-9. doi: 10.1016/j.amjcard.2010.08.062. Epub 2010 Dec 2.

PMID:
21129714
17.

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, Gregori D, Ciani F, Muzzi A, Klugmann S, Camerini F.

J Am Coll Cardiol. 1999 Jun;33(7):1926-34.

PMID:
10362195
18.

Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.

Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K.

Eur J Nucl Med Mol Imaging. 2005 Feb;32(2):186-94. Epub 2004 Sep 25.

PMID:
15452671
19.

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.

Circulation. 2004 Oct 26;110(17):2618-26. Epub 2004 Oct 18.

20.

Should beta-blockers form the cornerstone for the treatment of congestive heart failure?

Tabrizchi R.

Expert Rev Cardiovasc Ther. 2003 Jul;1(2):157-60. Review. No abstract available.

PMID:
15030275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk